Tyrosine Kinase Inhibitors and Vascular Adverse Events in Patients with Chronic Myeloid Leukemia: A Population-Based, Propensity Score-Matched Cohort Study
Journal
The oncologist
Date Issued
2021-08-21
Author(s)
Chen, Mei-Tsen
Huang, Shih-Tsung
Lin, Chih-Wan
Abstract
Tyrosine kinase inhibitors (TKIs) have shown long-term survival benefits in patients with chronic myeloid leukemia (CML). Nevertheless, significant concern has been raised regarding long-term TKI-associated vascular adverse events (VAEs). The objective of this retrospective cohort study was to investigate the incidence of VAEs in Taiwanese patients with CML treated with different TKIs (imatinib, nilotinib, and dasatinib) as well as potential risk factors.
Subjects
Chronic myeloid leukemia; Tyrosine kinase inhibitors; Vascular adverse events
SDGs
Other Subjects
acetylsalicylic acid; anticoagulant agent; antidiabetic agent; antihypertensive agent; antilipemic agent; antithrombocytic agent; cyclooxygenase 2 inhibitor; dasatinib; dihydroergotoxine; Ginkgo biloba extract; hydroxyurea; imatinib; neuroleptic agent; nicametate; nilotinib; pentoxifylline; piracetam; protein kinase inhibitor; adult; adverse drug reaction; Article; cerebrovascular disease; Charlson Comorbidity Index; chronic lung disease; chronic myeloid leukemia; clinical outcome; cohort analysis; congestive heart failure; dementia; diabetes mellitus; dyslipidemia; female; heart infarction; hormone substitution; human; hypertension; incidence; ischemic heart disease; ischemic stroke; kidney disease; liver disease; major clinical study; male; middle aged; peptic ulcer; peripheral occlusive artery disease; peripheral vascular disease; propensity score; retrospective study; rheumatic disease; risk factor; Taiwanese; venous thromboembolism; aged; Aged; Cohort Studies; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Propensity Score; Protein Kinase Inhibitors; Retrospective Studies
Type
journal article